Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ramucirumab - Eli Lilly and Company

Next Previous
Drug Profile

Ramucirumab - Eli Lilly and Company

Alternative Names: Anti-flk-1 monoclonal antibody - ImClone; Anti-KDR monoclonal antibody - ImClone; Anti-VEGFR 2 monoclonal antibody - ImClone; Cyramza; IMC-1121; IMC-1121-B; IMC-1C11 - ImClone; LY-3009806; Ramcilumab; ramsilmab; Ramsilomab; Ramsylmab; Ramsylumab; Sairamza; Silamza

Latest Information Update: 16 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dyax
  • Developer AstraZeneca; Basilea Pharmaceutica; Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Merck Sharp & Dohme; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer; Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer
  • Phase III Oesophageal cancer; Urogenital cancer
  • Phase II Biliary cancer; Carcinoid tumour; Solid tumours; Synovial sarcoma
  • Phase I/II Adenocarcinoma; Head and neck cancer; Pancreatic cancer; Soft tissue sarcoma
  • No development reported Breast cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 19 Jun 2025 Launched for Cancer in Denmark (IV)
  • 30 May 2025 Efficacy and adverse event data from the phase II CAMPFIRE trial in Soft tissue sarcoma and Synovial sarcoma is presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 18 Dec 2024 Launched for Gastric cancer in Hong Kong (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top